Active Gainers: Peregrine Pharmaceuticals (NASDAQ:PPHM), Alcatel Lucent (NYSE:ALU)

Pompano Beach, FL -- (SBWIRE) -- 01/07/2013 -- Among Biotech stocks Peregrine Pharmaceuticals (NASDAQ:PPHM) shares skyrocketed on Monday trading session as it provided Update on the Internal Review of Its Phase II Second-Line Non-Small Cell Lung Cancer Trial.

A biopharmaceutical firm that develops first-in-class monoclonal antibodies aimed towards the cure and diagnosis of cancer, on Monday gave an update from its internal assessment of inconsistencies from its Phase II randomized, double-blind placebo-controlled experiment of bavituximab in second-line non-small cell lung cancer (NSCLC) in 121 patients.

What was Peregrine Pharmaceuticals main goal behind this review? Find in this article

Our major goal in undertaking such a complete assessment was to recognize every feature of this clinical trial, Jeffrey L. Masten, vice president, quality of Peregrine articulated about the review.

Shares of Peregrine Pharmaceuticals (PPHM) boosted almost 80% during Monday’s trading session and were hanging around $2.41.

Shares of Alcatel Lucent (NYSE:ALU) were upgraded by Credit Suisse from an underperform rating to a neutral rating in a research report published on Thursday morning.

On what basis Alcatel Lucent was upgraded? Find in this report

A lot of other companies have also lately reported on ALU. Experts at Craig Hallum lifted their price target on stock of Alcatel Lucent from $1.50 to $2.50 in a research report to investors on Thursday, December 27th.

Now they have a buy rating on shares of the company. Moreover experts at Evercore Partners started coverage on shares of Alcatel Lucent in a research report given to investors on Monday, December 17th.

About No Limit Stocks
NOLIMITSTOCKS.com is made up of a team of professional analyst that possess over 30 years of expert, stock market experience. Our goal is to research thousands of companies and provide investors with the latest insights in the market with stocks that can make explosive profits. We study the hottest companies so you don't have to!

Our newsletter is always free to Join and offers a variety of useful investors tools that will help you break the limits! There will be no regrets!

Disclaimer
The assembled information disseminated by nolimitstocks.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. nolimitstocks.com does expect that investors will buy and sell securities based on information assembled and presented in nolimitstocks.com. PLEASE always do your own due diligence, and consult your financial advisor.